#1 Clinical Trials Search in Europe

Tocilizumab

Tocilizumab, a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has shown promising results in clinical trials for treating various conditions. This article explores the use of tocilizumab in clinical trials for diseases such as COVID-19, neuromyelitis optica spectrum disorders (NMOSD), rheumatoid arthritis, and lung transplantation. We’ll discuss its potential benefits, dosing strategies, and safety considerations across different patient populations.

Table of Contents

What is Tocilizumab?

Tocilizumab is a medication used to treat various inflammatory conditions. It’s also known by the brand names RoActemra and Actemra[1]. Tocilizumab is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein that mimics the immune system’s ability to fight off harmful pathogens such as viruses[2].

What Conditions Does Tocilizumab Treat?

Tocilizumab is used to treat several conditions, including:

  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting the joints[3].
  • COVID-19: Severe cases of COVID-19 associated with a cytokine storm (an overreaction of the immune system)[4].
  • Takayasu Arteritis: A rare type of blood vessel inflammation[5].
  • Fibrous Dysplasia of Bone: A bone disorder that causes abnormal growth patterns and fragile bones[6].

How Does Tocilizumab Work?

Tocilizumab works by blocking a protein in the body called interleukin-6 (IL-6). IL-6 is involved in causing inflammation in the body. By blocking IL-6, tocilizumab helps to reduce inflammation and relieve symptoms in various conditions[2].

In the case of COVID-19, tocilizumab is used to combat the “cytokine storm,” which is an overreaction of the immune system that can cause severe inflammation and damage to the lungs and other organs[4].

How is Tocilizumab Administered?

Tocilizumab can be administered in two main ways:

  1. Intravenous (IV) infusion: The medication is given directly into a vein. For example, in some COVID-19 studies, patients received 8 mg/kg of tocilizumab intravenously[4].
  2. Subcutaneous injection: The medication is injected under the skin. In some rheumatoid arthritis studies, patients received 162 mg of tocilizumab subcutaneously once a week[3].

The dosage and frequency of administration can vary depending on the condition being treated and the individual patient’s needs.

Effectiveness of Tocilizumab

The effectiveness of tocilizumab has been studied in various conditions:

  • Rheumatoid Arthritis: Studies have shown that tocilizumab can help reduce disease activity and improve physical function in patients with RA[7].
  • COVID-19: Some studies have suggested that tocilizumab may help reduce mortality and the need for mechanical ventilation in severe COVID-19 cases[4].
  • Takayasu Arteritis: Research has indicated that tocilizumab may be effective as a first-line treatment for inducing remission in this condition[5].

Potential Side Effects

Like all medications, tocilizumab can cause side effects. Some potential side effects include:

  • Increased risk of infections
  • Headache
  • High blood pressure
  • Abnormal liver function tests
  • Allergic reactions

It’s important to discuss potential side effects with your healthcare provider before starting treatment[7].

Ongoing Research and Future Prospects

Research on tocilizumab is ongoing, with several clinical trials investigating its use in various conditions:

  • Its effectiveness in early, moderate to severe rheumatoid arthritis[8].
  • Its potential in treating cytokine release syndrome associated with COVID-19[9].
  • Its use in fibrous dysplasia of bone for patients who don’t respond to other treatments[6].

These ongoing studies may lead to new applications for tocilizumab in the future, potentially benefiting more patients with inflammatory conditions.

Condition Dosage Key Outcomes Measured Potential Benefits
COVID-19 Pneumonia 4-8 mg/kg IV Mortality rate, time to recovery, CRP levels Reduced inflammation, improved respiratory function
Neuromyelitis Optica Spectrum Disorders (NMOSD) 8 mg/kg IV every 4-6 weeks Relapse rate, disability progression, visual function Reduced relapse frequency, improved neurological function
Rheumatoid Arthritis 162 mg SC weekly or every 2 weeks Disease activity scores, drug levels Optimized dosing, reduced disease activity
Lung Transplantation Not specified CLAD development, re-transplantation rates, survival Reduced inflammation, improved graft survival

FAQ

  • What is tocilizumab and how does it work? Tocilizumab is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor. It works by blocking the IL-6 signaling pathway, which plays a role in inflammation and immune responses. By inhibiting this pathway, tocilizumab can help reduce inflammation and symptoms in various conditions.
  • In which conditions is tocilizumab being studied? Tocilizumab is being studied in clinical trials for several conditions, including COVID-19 pneumonia, neuromyelitis optica spectrum disorders (NMOSD), rheumatoid arthritis, and in lung transplant recipients. It shows potential in reducing inflammation and improving outcomes in these diverse conditions.
  • What are the potential benefits of tocilizumab in COVID-19 treatment? In COVID-19 clinical trials, tocilizumab is being studied for its potential to reduce inflammation, improve respiratory function, and decrease mortality rates in patients with severe COVID-19 pneumonia. Some studies are exploring its effectiveness in preventing the need for invasive mechanical ventilation and reducing hospital length of stay.
  • How is tocilizumab administered in clinical trials? The administration of tocilizumab varies depending on the condition and specific trial. In most studies, it is given intravenously (IV) at doses ranging from 4 mg/kg to 8 mg/kg. Some trials are exploring lower doses or different dosing intervals to optimize treatment while minimizing side effects.
  • What are the potential side effects of tocilizumab? Common side effects of tocilizumab may include infections, gastrointestinal perforations, and changes in liver function tests. Clinical trials are closely monitoring for adverse events, including serious infections, malignancies, and tuberculosis. The safety profile is being evaluated in different patient populations to determine the best use of the drug.

Ongoing Clinical Trials on Tocilizumab

  • Testing a Drug Combination for Personalized Sepsis Treatment in Children and Adults with Severe Blood Infection

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Denmark France Germany Italy +3

  • Study of tocilizumab compared to placebo in patients with chronic chondrocalcinosis who did not respond to standard treatments

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Evaluating Safety and Effectiveness of Combining Biologic Medications for Patients with Rheumatoid Arthritis and Psoriatic Arthritis ## Human: Give a detailed summary of a clinical trial for patients: 1.

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study on Adjusting Tocilizumab Doses for Patients with Rheumatoid Arthritis

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study Comparing Conventional Therapy and Biologic Treatments for Early Rheumatoid Arthritis Using Hydroxychloroquine, Abatacept, and Azathioprine in Responsive Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Iceland Norway Sweden

  • Study on Rituximab, Tocilizumab, and Tofacitinib for Patients with Granulomatosis with Polyangiitis Not Responding to Standard Therapy

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

    Not yet recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Croatia Hungary

Glossary

  • Tocilizumab: A humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, used to treat various inflammatory conditions.
  • Interleukin-6 (IL-6): A protein produced by the body that plays a role in immune responses and inflammation.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific targets in the body, such as on the surface of cells.
  • COVID-19 pneumonia: Inflammation of the lungs caused by the SARS-CoV-2 virus, which can lead to severe respiratory problems.
  • Neuromyelitis optica spectrum disorders (NMOSD): A group of rare autoimmune conditions that primarily affect the optic nerves and spinal cord.
  • Rheumatoid arthritis: A chronic inflammatory disorder that primarily affects the small joints of the hands and feet.
  • Lung transplantation: A surgical procedure to replace a diseased or failing lung with a healthy lung from a donor.
  • C-reactive protein (CRP): A protein produced by the liver in response to inflammation, often used as a marker of inflammation in the body.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Chronic Lung Allograft Dysfunction (CLAD): A form of chronic rejection that can occur after lung transplantation, leading to declining lung function.

References

  1. https://clinicaltrials.gov/study/NCT02552940
  2. https://clinicaltrials.gov/study/NCT04331808
  3. https://clinicaltrials.gov/study/NCT02011334
  4. https://clinicaltrials.gov/study/NCT04730323
  5. https://clinicaltrials.gov/study/NCT02101333
  6. https://clinicaltrials.gov/study/NCT01791842
  7. https://clinicaltrials.gov/study/NCT01649804
  8. https://clinicaltrials.gov/study/NCT01730456
  9. https://clinicaltrials.gov/study/NCT04424056